期刊文献+

强直性脊柱炎与妊娠 被引量:1

Ankylosing spondylitis and pregnancy
下载PDF
导出
摘要 强直性脊柱炎(AS)是一种慢性系统性炎性疾病,主要累及骶髂关节和脊柱附着点,以软骨关节和滑膜关节以及肌腱、韧带附着于骨的部位的纤维化和骨性强直为主要病变特点,并可伴发外周关节及关节外的表现。AS在我国患病率初步调查为0.3%左右。近年来,该病的女性患者逐渐增多,对女性患者,特别是育龄期女性在妊娠前后及妊娠过程中免疫变化,以及药物治疗等都对母亲及胎儿都有一定影响,此文将对这方面的进展情况进行综述。 Ankylosing spondylitis (AS) is a chronic inflammatory disease that encroaches sacroiliac joint and process of bone of vertebral column, with the fibrosis and osseous ankylosis of parts including spine soft tissue, peripher- al joints, attachment parts of tendons and ligaments to the bone as the main pathological features, and can be associated with peripheral joints and extra articular manifestations. The prevalence of AS in China was about 0.3%. In recent years, female patients gradually increased, female patients, especially women of childbearing age before and after pregnancy and pregnancy in the immune changes, as well as drug treatment and so on have a certain impact on the mother and the fetus. This article will review the progress on ankylosing spondylitis and pregnancy.
作者 王丽君 田梅 WANG Li-jun, TIAN Mei(Zunyi Medical College, Zunyi 563000, Guizhou, CHIN)
机构地区 遵义医学院
出处 《海南医学》 CAS 2018年第6期827-830,共4页 Hainan Medical Journal
关键词 强直性脊柱炎 妊娠 治疗 Ankylosing spondylitis (AS) Pregnancy Treatment
  • 相关文献

二级参考文献25

  • 1Flint J, Panchal S, Huh'ell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breasffeeding-Part II: anal- gesics and other drugs used in rheumatology practice [J]. Rheu- matology (Oxford),2016, pii: kev405. [ Epub ahead of print ].
  • 2Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: stan- dard and biologic disease modifying anti-rheumatic drugs and corticosteroids [J]. Rheumatology (Oxford),2016, 55 (9) : 1693- 1697.
  • 3Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammato- ry and immunosuppressive drugs and reproduction [J]. Arthritis Res Ther,2006,8(3):209.
  • 4Motta M, Ciardelli L, Marconi M, et al. Immune system develop- ment in infants born to mothers with autoimmune disease, ex- posed in utero to immunosuppressive agents [J ]. Am J Perinatol, 2007,24(8):441-447.
  • 5Gotestam SC, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnan- cy, and during pregnancy and lactation [J]. Ann Rheum Dis, 2016,75(5):795-810.
  • 6Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnan- cy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter co- hort study [ J ]. Arthritis Rheumatol,20i 4,66(5): 1101 - 1110.
  • 7Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohortstudy[J]. Rheumatology (Oxford),2014,53(4):757-763.
  • 8Levi S, Liberman M, Levi A J, et al. Reversible congenital neu- tropenia associated with maternal sulphasalazine therapy [J]. EurJ Pediatr,1988,148(2): 174-175.
  • 9Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy [J]. Arthritis Rheum,2010,62(5): 1494-1503.
  • 10Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumat- ic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers [J]. Scand J Rheumatol,2012,41 (3): 196-201.

共引文献870

同被引文献12

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部